All Curated Mutation Sites in HBV

The Virus Mutation(VM) module provides researchers the annotations of reported pathogenic mutations in HBV related to human diseases. The curated VM information includes mutation site, mutation level, virus gene/protein/region, virus-associated disease, genotype/subtype, literature evidence, etc.

Browse Data by Virus Gene/Protein/Region, Disease OR Description

*Please select one option you are interested in, the page will be automatically redirected.

Virus Gene/Protein

Disease

Description

For highly variable viruses (e.g., HBV, HIV, SARS-CoV-2), ViMIC defaults to displaying mutations in a specific region. Click the green button to search for other regions, or click "Show All" to view all mutations (loading speed may be affected by network conditions).

Show All

BCP

Core Promoter

Core Upstream Regulatory Sequence

Keyword: Hepatitis B Virus Infection-31952213

ID	PMID	Mutation	Gene/Protein/Region	Encoding Gene/Protein	Disease	Description	Detail
1	31952213	C2964A	PreS1	S	Hepatitis B Virus Infection	G R L	View
2	31952213	I91L	RT	P	Hepatitis B Virus Infection	G R L	View
3	31952213	N3S	S	S	Hepatitis B Virus Infection	G R L	View
4	31952213	H9Y	RT	P	Hepatitis B Virus Infection	G R L	View
5	31952213	I269L	RT	P	Hepatitis B Virus Infection	G R L	View
6	31952213	N13H	RT	P	Hepatitis B Virus Infection	G R L	View
7	31952213	V278I	RT	P	Hepatitis B Virus Infection	G R L	View
8	31952213	C3062T	PreS1	S	Hepatitis B Virus Infection	G R L	View
9	31952213	A177V	S	S	Hepatitis B Virus Infection	G R L	View
10	31952213	E44G	S	S	Hepatitis B Virus Infection	G R L	View
11	31952213	I213L	S	S	Hepatitis B Virus Infection	G R L	View
12	31952213	S210N	S	S	Hepatitis B Virus Infection	G R L	View
13	31952213	S53L	S	S	Hepatitis B Virus Infection	G R L	View
14	31952213	V159A	S	S	Hepatitis B Virus Infection	G R L	View
15	31952213	V18G	S	S	Hepatitis B Virus Infection	G R L	View

Contents
Description

The table shows all curated mutation sites of HBV in each literature

Table Description Column Note

D
The study mentioned a certain treatment method, such as drug resistance caused by mutations.

G
The study mentioned the virus genotype/subtype information.

R
The study mentioned the reference sequence used for comparison, or the original strain of the virus used for site-directed mutagenesis.

S
The study provided sequence information or accession numbers.

L
The study provided the geographic region/country of data origin.

C
The study provided clinical baseline information.

I
The study involved information related to immune.

T
The study involved host target genes.